Abstract:BACKGROUND:The genome of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) includes sequences encoding the putative protein X4 (ORF8, ORF7a), consisting of 122 amino acids. The deduced sequence contains a probable cleaved signal peptide sequence and a C-terminal transmembrane helix, indicating that protein X4 is likely to be a type I membrane protein. This study was conducted to demonstrate whether the protein X4 was expressed and its essential function in the process of SARS-CoV infection.METHODS:The prokaryotic and eukaryotic protein X4-expressing plasmids were constructed. Recombinant soluble protein X4 was purified from E. coli using ion exchange chromatography, and the preparation was injected into chicken for rising specific polyclonal antibodies. The expression of protein X4 in SARS-CoV-infected Vero E6 cells and lung tissues from patients with SARS was performed using immunofluorescence assay and immunohistochemistry technique. The preliminary function of protein X4 was evaluated by treatment with and over-expression of protein X4 in cell lines. Western blot was employed to evaluate the expression of protein X4 in SARS-CoV particles.RESULTS:We expressed and purified soluble recombinant protein X4 from E.coli, and generated specific antibodies against protein X4. Western blot proved that the protein X4 was not assembled in the SARS-CoV particles. Indirect immunofluorescence assays revealed that the expression of protein X4 was detected at 8 hours after infection in SARS-CoV-infected Vero E6 cells. It was also detected in the lung tissues from patients with SARS. Treatment with and overexpression of protein X4 inhibited the growth of Balb/c 3T3 cells as determined by cell counting and MTT assays.CONCLUSION:The results provide the evidence of protein X4 expression following SARS-CoV infection, and may facilitate further investigation of the immunopathological mechanism of SARS.

[Preparation and Identification of Monoclonal Antibodies Against SARS-CoV Putative Protein X4].

The Protein X4 of Severe Acute Respiratory Syndrome-Associated Coronavirus is Expressed on Both Virus-Infected Cells and Lung Tissue of Severe Acute Respiratory Syndrome Patients and Inhibits Growth of Balb/c 3T3 Cell Line.

Monoclonal neutralizing antibodies against SARS-COV-2 S protein

Identification of Four Linear B-cell Epitopes on the SARS-CoV-2 Spike Protein Able to Elicit Neutralizing Antibodiesidentification of Four Linear B-cell Epitopes on the SARS-CoV-2 Spike Protein Able to Elicit Neutralizing Antibodies

Computational identification of epitopes in the glycoproteins of novel bunyavirus (SFTS virus) recognized by a human monoclonal antibody (MAb 4-5)

In Vitro Expression of SARS Coronavirus(sars-Cov)nucleocapsid Protein and Examination of the Function of Monoclonal Antibody Induced by the Expressed Protein

Structure-guided Affinity Maturation of a Novel Human Antibody Targeting the SARS-CoV-2 Nucleocapsid Protein

Preparation and Identification of Monoclonal Antibody Against C1q/TNF-Related Protein 4.

A human neutralizing antibody against a conforma- tional epitope shared by oligomeric SARS S1 protein

Conserved Amino Acids W423 and N424 in Receptor-Binding Domain of SARS-CoV Are Potential Targets for Therapeutic Monoclonal Antibody.

Identification of Human Single-Domain Antibodies Against SARS-CoV-2.

Identification and Characterization of Novel Neutralizing Epitopes in the Receptor-Binding Domain of SARS-CoV Spike Protein: Revealing the Critical Antigenic Determinants in Inactivated SARS-CoV Vaccine.

Isolation and Identification of an Scfv Antibody Against Nucleocapsid Protein of SARS-CoV.

[Preparation of the Monoclonal Antibody Against SOX4 Protein and Detection of SOX4 Expression Level in Different Tumor Cell Lines].

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes

[Preparation, Purification and Characterization of the Polyclonal Antibody Against Human CMTM4].

Preparation and characterization of antibodies against murine coronavirus nucleocapsid protein

A Strategy for Searching Antigenic Regions in the SARS-CoV Spike Protein

Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.

A New Strategy: Identification of Specific Antibodies for Neutralizing Epitope on SARS-CoV-2 S Protein by LC-MS/MS Combined with Immune Repertoire

Protective Humoral Responses to Severe Acute Respiratory Syndrome-Associated Coronavirus: Implications for the Design of an Effective Protein-Based Vaccine.